(Return tabled) Question No. 1340 Mr. Matthew Kellway: With regard to the issue of the proposed for-profit blood plasma clinics in Toronto and Hamilton, Ontario: (a) when was Health Canada approached by the operators of the proposed for-profit blood plasma clinics; (b) how many consultations took place between Health Canada and the operators of the proposed for-profit blood plasma clinics; (c) how many consultations took place between Health Canada and (i) Canadian Blood Services, (ii) the province of Ontario; (d) when did these consultations take place and if no consultations took place, how did Health Canada determine that consultat ...[+++]ions were not necessary; (e) when were the locations for the proposed clinics approved; (f) what process did the operators of the proposed for-profit blood plasma clinics follow to obtain approval for the location of the clinics; (g) what is Health Canada’s policy on the operation of for-profit blood plasma clinics in Canada; (h) what is Health Canada’s policy with regard to following the recommendations of the Royal Commission of Inquiry on the Blood System in Canada (“Krever report”); (i) what existing statutes, regulations, auditing processes, etc. are in place to ensure the safety of Canada’s blood supply; (j) with regard to ensuring the safety of Canada’s blood supply, what is the regulatory role of (i) Health Canada, (ii) the province, (iii) Canadian Blood Services; (k) what role does Canadian Blood Services play in the establishment or regulation of for-profit blood plasma clinics in Canada; (l) what does Health Canada’s auditing process for licensing for-profit blood plasma clinics in Canada involve; (m) what information is provided to Health Canada by the operators; (n) how often does Health Canada audit these clinics; and (o) what is the relationship between Health Canada and the U.S. Food and Drug Administration in ensuring the safety of blood plasma products purchased from the United States of America?

CVD includes the following processes: directed gas flow out-of-pack deposition, pulsating CVD, controlled nucleation thermal deposition (CNTD), plasma enhanced or plasma assisted CVD processes.

d. Plasma Spraying is an overlay coating process wherein a gun (spray torch) which produces and controls a plasma accepts powder or wire coating materials, melts them and propels them towards a substrate, whereon an integrally bonded coating is formed.

5. Ion Plating is a special modification of a general TE-PVD process in which a plasma or an ion source is used to ionise the species to be deposited, and a negative bias is applied to the substrate in order to facilitate the extraction of the species from the plasma.

d. Plasma Spraying is an overlay coating process wherein a gun (spray torch) which produces and controls a plasma accepts powder or wire coating materials, melts them and propels them towards a substrate, whereon an integrally bonded coating is formed.

The plasma extracted in accordance with E (a) may be used immediately after centrifuging, no thermal stabilization being necessary.